News | May 21, 2015

Data Confirms Safety of Iforia ProMRI ICD in 1.5 Tesla MRI Scanning Conditions

May 21, 2015 — The Phase C results of the ProMRI Clinical Study were presented at the late-breaking clinical trial session of the Heart Rhythm Society (HRS) 2015 meeting. Khaled A. Awad, M.D., assistant professor of medicine at University of Alabama-Birmingham School of Medicine, presented the findings at HRS. The completed study has been submitted to the U.S. Food and Drug Administration (FDA) to support approval of the Biotronik Iforia ProMRI implantable cardioverter defibrillator (ICD) system.

A total of 170 ICD patients were enrolled at 39 clinical sites in the United States, of which 154 received thoracic spine (74.3 percent) or cardiac (25.7percent) MRI scans. Of these patients, 61.7 percent had been implanted with the Iforia DX ICD, and the remainder with the Iforia DR-T ICD. All three of the study’s primary endpoints were met with statistical significance. Considered a critical safety endpoint, the observed change in the ventricular pacing threshold between the pre-MRI and one-month post-MRI observation period was only 0.01 V. Similarly, the change in R-wave amplitude during this period was -0.47 mV. There were no reports of device-related serious adverse events during the trial.
 
“Like all of the investigators who have contributed, I am pleased to lead the charge to new horizons of diagnostic imaging for cardiac device patients,” Awad said. “Even cardiac imaging had no significant effect on device performance. Importantly, we had multiple patients who had spontaneous ventricular arrhythmia episodes that were appropriately detected and treated by the Iforia ICD in the post-MRI follow-up period. These life-saving devices were able to function as designed, completely unaffected by the MRI scan.”
 
Phase C of the ProMRI trial is the latest phase in a series of ground-breaking MRI compatibility trials conducted by Biotronik in rapid succession. Phase A and Phase B of the trial evaluated the safety of Entovis pacemaker systems during MRI scans. Eluna and Entovis ProMRI pacemaker systems were FDA-approved for full-body MRI scans in March 2015.
 
Every year, about 200,000 patients in the U.S. are implanted with ICDs, and studies estimate that 50 to 75 percent of them will develop a clinical need for an MRI scan during their lifetime.  The strong magnetic forces applied during an MRI scan can, however, have a negative effect on both device and patient. Therefore, pacemaker and ICD patients are usually contraindicated for MRI scans. With its ProMRI technology, Biotronik has developed a solution that grants all cardiac-rhythm patients access to MRI scanning. ProMRI technology is already widely used in Europe, where recent CE approval was given for MR conditional full-body and 3.0 Tesla scans with the Ilesto/Iforia ICD system.
 
The Biotronik-sponsored trial (NCT01761162) started U.S. patient recruitment in March 2013.
 
 

Related Content

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

Hershey's Chocolate display with samples and coco pods at the American College of Cardiology (ACC) 2012 annual meeting. The company was making the case that chocolate can be good for your heart, which is now supported by several studies. Photo by Dave Fornell

News | Cardiovascular Clinical Studies | July 22, 2020
July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to re
The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp